Your institution may have access to this item. Find your institution then sign in to continue.
Title
Everolimus.
Authors
Atkins, Michael B.; Yasothan, Uma; Kirkpatrick, Peter
Abstract
In March 2009, everolimus (Afinitor; Novartis), an inhibitor of mTOR, was approved by the US FDA for the treatment of patients with advanced kidney cancer.
Publication
Nature Reviews Drug Discovery, 2009, Vol 8, Issue 7, p535